News
Video
Author(s):
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies
Revisit the OncLive On Air Episodes From February 2024
P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma
Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment